Vaxart Statistics
Total Valuation
Vaxart has a market cap or net worth of 147.10 million. The enterprise value is 96.34 million.
| Market Cap | 147.10M |
| Enterprise Value | 96.34M |
Important Dates
The next estimated earnings date is Thursday, May 14, 2026.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Vaxart has 241.15 million shares outstanding. The number of shares has increased by 13.96% in one year.
| Current Share Class | 241.15M |
| Shares Outstanding | 241.15M |
| Shares Change (YoY) | +13.96% |
| Shares Change (QoQ) | +3.16% |
| Owned by Insiders (%) | 2.74% |
| Owned by Institutions (%) | 0.17% |
| Float | 234.54M |
Valuation Ratios
The trailing PE ratio is 8.71 and the forward PE ratio is 2.10.
| PE Ratio | 8.71 |
| Forward PE | 2.10 |
| PS Ratio | 0.62 |
| PB Ratio | 1.68 |
| P/TBV Ratio | 1.83 |
| P/FCF Ratio | 19.43 |
| P/OCF Ratio | 19.07 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 2.84, with an EV/FCF ratio of 12.73.
| EV / Earnings | 5.90 |
| EV / Sales | 0.41 |
| EV / EBITDA | 2.84 |
| EV / EBIT | 5.33 |
| EV / FCF | 12.73 |
Financial Position
The company has a current ratio of 1.57, with a Debt / Equity ratio of 0.15.
| Current Ratio | 1.57 |
| Quick Ratio | 1.33 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | 0.38 |
| Debt / FCF | 1.72 |
| Interest Coverage | 6.40 |
Financial Efficiency
Return on equity (ROE) is 22.26% and return on invested capital (ROIC) is 65.10%.
| Return on Equity (ROE) | 22.26% |
| Return on Assets (ROA) | 6.41% |
| Return on Invested Capital (ROIC) | 65.10% |
| Return on Capital Employed (ROCE) | 18.20% |
| Weighted Average Cost of Capital (WACC) | 12.28% |
| Revenue Per Employee | 3.65M |
| Profits Per Employee | 251,185 |
| Employee Count | 65 |
| Asset Turnover | 1.35 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Vaxart has paid 476,000 in taxes.
| Income Tax | 476,000 |
| Effective Tax Rate | 2.83% |
Stock Price Statistics
The stock price has increased by +69.13% in the last 52 weeks. The beta is 1.32, so Vaxart's price volatility has been higher than the market average.
| Beta (5Y) | 1.32 |
| 52-Week Price Change | +69.13% |
| 50-Day Moving Average | 0.66 |
| 200-Day Moving Average | 0.46 |
| Relative Strength Index (RSI) | 43.12 |
| Average Volume (20 Days) | 526,295 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.00 |
Income Statement
In the last 12 months, Vaxart had revenue of 237.26 million and earned 16.33 million in profits. Earnings per share was 0.07.
| Revenue | 237.26M |
| Gross Profit | 35.68M |
| Operating Income | 18.07M |
| Pretax Income | 16.80M |
| Net Income | 16.33M |
| EBITDA | 26.65M |
| EBIT | 18.07M |
| Earnings Per Share (EPS) | 0.07 |
Balance Sheet
The company has 63.81 million in cash and 13.05 million in debt, with a net cash position of 50.76 million or 0.21 per share.
| Cash & Cash Equivalents | 63.81M |
| Total Debt | 13.05M |
| Net Cash | 50.76M |
| Net Cash Per Share | 0.21 |
| Equity (Book Value) | 87.80M |
| Book Value Per Share | 0.37 |
| Working Capital | 49.37M |
Cash Flow
In the last 12 months, operating cash flow was 7.71 million and capital expenditures -145,000, giving a free cash flow of 7.57 million.
| Operating Cash Flow | 7.71M |
| Capital Expenditures | -145,000 |
| Depreciation & Amortization | 8.58M |
| Net Borrowing | n/a |
| Free Cash Flow | 7.57M |
| FCF Per Share | 0.03 |
Margins
Gross margin is 15.04%, with operating and profit margins of 7.62% and 6.88%.
| Gross Margin | 15.04% |
| Operating Margin | 7.62% |
| Pretax Margin | 7.08% |
| Profit Margin | 6.88% |
| EBITDA Margin | 11.23% |
| EBIT Margin | 7.62% |
| FCF Margin | 3.19% |
Dividends & Yields
Vaxart does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.96% |
| Shareholder Yield | -13.96% |
| Earnings Yield | 11.10% |
| FCF Yield | 5.15% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Vaxart has an Altman Z-Score of -0.92 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.92 |
| Piotroski F-Score | 6 |